Current investigations are focused on understanding whether NNMT inhibition might influence cancer progression or aggressiveness
This minimizes the time the reconstituted solution sits in the refrigerator
All current research is in animal models human clinical trials are limited so it remains strictly a research compound at this stage
\n\n\n\n From a sports and athletics perspective, BPC-157 is monitored by WADA (the World Anti-Doping Agency) under its category of peptide hormones, growth factors, and related substances
The peptide is constructed on a GIP receptor backbone with non-coded amino acid residues (Aib2, Aib20, aMeL13) and a C20 fatty diacid moiety that enables albumin binding, extending pharmacokinetic half-life for once-weekly administration in research settings
Each of us is differently affected and require a different frequency of B12 injections